Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
Portfolio Pulse from Benzinga Insights
Analysts have varied opinions on Vir Biotechnology (NASDAQ:VIR), with 6 ratings over the past three months showing a mix of bullish and indifferent stances. The average 12-month price target for VIR is $61.17, significantly up from the previous $34.67. Recent analyst actions include maintaining and raising ratings, with price targets ranging from $10.00 to $110.00. Vir Biotechnology, an immunology company, has shown a revenue growth of 9.62% as of March 31, 2024, but faces challenges in ROA and achieving average growth rates in the Health Care sector.
May 07, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vir Biotechnology has received mixed analyst ratings, with an updated average price target of $61.17, indicating a significant positive revision from $34.67. The company's recent financial performance shows a revenue growth of 9.62%, despite challenges in ROA and sector growth rates.
The significant increase in the average price target by analysts suggests a bullish outlook for Vir Biotechnology, likely due to its recent revenue growth and strategic position in the immunology sector. However, the mixed ratings and challenges in asset utilization and sector growth rates indicate potential volatility. The high relevance score is due to the direct mention and detailed analysis of VIR in the article.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100